PGD worldwide experience includes close to 50,000 PGD cycles performed by more than 100 centers around the world. The majority of PGD (more than 40,000 cycles) were for aneuploidy testing, up to 6,000 for Mendelian disorders, and approximately, 3,000 for translocations. An increasing number of cases (over 600) is being performed for preimplantation HLA typing.

PGD impact on assisted reproduction and genetic practices:

• allows at risk couples to avoid birth of child with Mendelian disease without facing risk of pregnancy termination in routine prenatal diagnosis



• improves implantation and take home baby rates in poor prognosis IVF patients



• reduces four-fold spontaneous abortions in carriers of chromosomal translocations



• allows forgoing pregnancy for couples at risk for producing offspring with late-onset disorders with genetic predisposition



• allows producing an HLA matched offspring for treatment of siblings requiring HLA matched stem cells transplantation



• provides an unlimited source of human embryonic stem cell lines with normal and abnormal genotypes